Key Takeaways
- Margin expansion despite revenue softness: EBITDA margin improved 291 bps YoY driven by input cost moderation and a richer order mix, even as Q1 revenue booking was subdued by site-heavy execution and election-led domestic delays.
- Order intake hit by policy freeze, not competition: Q1 order intake fell short because central elections and unresolved feedstock bans froze domestic project decisions and bank funding; management explicitly stated no market share was lost.
- International pivot is accelerating and margin-accretive: Export orders now 42% of the order book, up sharply, and carry structurally higher margins because they exclude low-margin EPC construction work.
- The GenX facility is a near-term margin drag with a clear payoff path: First equipment shipped, but the Mangalore plant is still ramping up and carrying expenses; revenue generation begins H2, with full potential of ₹2,000–2,500 cr targeted in roughly two years.
- What to watch next quarter: Whether the domestic feedstock freeze lifts and unlocks the stalled inquiry pipeline, the pace of GenX revenue ramp-up, and progress on the half-dozen SAF projects in global dialogue.
Margin Drivers & Profitability
- Contribution margin up ~4%: Roughly 2% came from softening input costs on old fixed-price contracts where material was procured at lower prices, and 1.5–2% from a favorable order composition shift toward higher-margin export and engineering orders.
- Export vs domestic margin structure: Export orders carry higher margins because they involve only technology and equipment supply, whereas domestic orders include lower-margin EPC construction work. This structural gap makes the rising export share a durable margin tailwind.
- Fixed-price contract risk is inherent: Contracts carry no pass-through mechanism for input cost changes, so margin gains from softening input costs can reverse if material prices rise. Management expects input costs to remain range-bound with no significant volatility anticipated.
- Input cost benefit has a shelf life: The positive from softening input costs will continue only until old orders priced at higher material costs are executed; beyond that, the benefit normalizes.
- Site-heavy Q1 depressed reported revenue: Revenue booking was lower because site expenses sit in other expenses rather than procurement margin, so higher site activity in the quarter shifted costs below the gross margin line.
Joshipura: "We are no longer dependent on a single molecule in a single market. We are now multiple markets, multiple molecules, multiple solutions, multiple capabilities that we can get paid for."
Domestic Bioenergy: The Policy Overhang
- Feedstock freeze froze the market: Unresolved clearance on molasses B/syrup and the embargo on rice from FCI, combined with central elections, caused prospective customers to defer decisions and bankers to withhold project funding. The first two months of the quarter were largely lost.
- Starchy feedstock now dominates the order book: Over 75% of the domestic order book is from starchy feedstock based plants, reflecting a structural shift in feedstock mix even as policy uncertainty persists on other feedstocks.
- Inquiry pipeline remains healthy but stalled: Domestic ethanol demand is not at the "hay day level" of capacity creation, but activity continues; two major feedstocks remain on freeze and zone restrictions add complexity.
- CBG ecosystem developing gradually: Liquid fertilizer, solid fertilizer, gas supply chains, and user points like CNG vehicles are coming into place; the SATAT scheme envisages a larger outlay, and the blending mandate becomes compulsory in roughly 18 months. Management expects projects to move in H2.
- Grain-based ethanol directive is a tailwind: A clear directive toward maize-based production, combined with improving maize availability, is expected to improve feedstock equilibrium.
Joshipura: "Difficult to answer it just now." [on when the feedstock freeze will be unfrozen]
International Expansion & Order Wins
- Lactose-based low carbon ethanol order won: A first-of-its-kind order from a US customer in Michigan to produce low carbon ethanol using lactose separated from milk; qualifies for a very low carbon intensity score. Amul has launched milk in the US and the same dairy will be the production point.
- SAF modularization contract awarded: A full-scale engineering and modularization contract for a large commercial ATJ SAF project in the United States; engineering will take 6–8 months, with better visibility on project cost expected in roughly six months.
- SAF pipeline is broad: Management is in dialogue with at least half a dozen SAF projects globally; domestic traction is expected toward the end of this calendar year as CORSIA's 1% mandatory blending for international flights kicks in January 2027, and project cycles run 18–24 months.
- Brazil grain-based ethanol in advanced negotiation: Several strong leads; the Brazil model involves phased contracting, starting with engineering before moving to full project execution, which lengthens the conversion cycle.
- CBG pilot plant in the US: A pilot plant is being set up to test RNG generation from waste-stream in a grain-to-ethanol project, with a focus on solving effluent management after gas generation and making the solution compatible with local fertilizer laws.
- Biogenic CO2 capture contracts won: Contracts secured for Thailand and Zambia.
- Carbon capture contract in Europe: A modularized solution contract received for a blue hydrogen project in Europe.
- Local team build-out underway: Praj is building a local team in international markets with natives of those places to support the expanding footprint.
Joshipura: "Usually, one would expect that you will get the full contract on day one, that's not the way Brazil works. So, they would like to go through the steps of first engineering, finish the engineering, and then get a firm grip on the overall project cost, and then move forward with the establishment of project."
GenX Facility & Capacity Build-Out
- First equipment manufactured and shipped: The Mangalore GenX facility has completed its first equipment and shipped the consignment; the facility is now fully functional with necessary certifications obtained, and customers can now specify it in contracts.
- Ramp-up timeline is gradual: Actual production is expected to start rolling out toward the end of this calendar year, reaching full force in the next financial year; management targets 70–80% of the ₹2,000–2,500 cr revenue potential within roughly two years from the start of production.
- Near-term margin drag: The facility is in ramp-up phase with expenses continuing; revenue generation is expected from H2, which will begin to normalize the cost burden seen in Q1.
- CAPEX for FY25: ₹75 to ₹100 crores, allocated across GenX (not yet fully done), the PLA side, pilot plants for R&D, and the IOCL JV depending on how many projects kick-start this year or next.
Technology & New Molecules
- Biopolymer milestone achieved: Praj became the first Indian company to indigenously develop technology for lactic acid and lactide, producing the first batch of lactic acid 90% at a newly set up demonstration plant at Jejuri.
- 2G IOCL plant recommissioning underway: Work is progressing as per plan with the IOCL team to resolve unique situations and ramp up production gradually; full-scale commissioning is targeted by the end of this calendar year.
- Spain 2G feasibility study commenced: A feasibility study for a straw-based ethanol plant in Spain for a Spanish multinational; management cautioned this is a first step and the project is a long way away.
- Centre of Excellence established: Set up with Vasantdada Sugar Institute for integration of farm-to-fuel model, focusing on alternate feedstock through intercropping models like sweet sorghum with sugarcane and maize with cassava.
- LCE without carbon capture is a differentiator: Praj's offering can reduce the carbon intensity score by nearly 30 points even without carbon capture and sequestration, expanding the addressable market for low carbon ethanol.
Joshipura: "What is sufficient for me to say right now is that this is a huge step forward towards an era of biopolymer, bioplastic manufacturing in the country using indigenous feedstocks and indigenous technology."
Order Book & FY25 Outlook
- Order book composition has structurally shifted: The engineering/PHS section is now at a 52:48 ratio versus 80:20 previously; export business is at 42% of the order book. Management emphasized these steps were taken thoughtfully over time, not rushed.
- FY25 order booking expected to improve: Management expects to do better than the previous year, with improvement becoming visible as the year progresses; the four factors that depressed Q1 intake are seen as temporary.
- No revenue guidance given: Management explicitly declined to provide revenue guidance, with the CEO joking that his CFO "forgets his mathematics" when the question is asked.
- 3x growth by 2030 remains on track: Management stated there is no reason to believe otherwise, subject to things remaining normal, referencing the disruptions of 2022.
- Working capital stable: No pressure expected; even with revenue growth, working capital days will remain similar to last year.
- IOCL JV progressing: Capital allocation will happen depending on how many projects kick-start this year or next; a CBG plus SAF plant is "on the anvil," and funding will be explored from different avenues, not necessarily entirely from Praj's side.
Joshipura: "Sorry to disappoint you we don't give revenue number guidance. When you talk revenue guidance, my CFO forget his mathematics, he is otherwise a brilliant guy, but he forgets."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| GenX revenue generation | Revenue to begin from Mangalore facility | H2 FY25 |
| GenX full potential | 70–80% of ₹2,000–2,500 cr revenue capacity | ~2 years from start of production |
| 2G IOCL plant commissioning | Full-scale commissioning targeted | End of calendar year 2024 |
| SAF project cost visibility | Better view on project cost after engineering completion | ~6 months |
| Domestic SAF traction | Major traction expected as CORSIA mandate nears | End of calendar year 2024 |
| CBG blending mandate | Becomes compulsory | ~18 months |
| FY25 CAPEX | ₹75–100 crores | FY25 |
| FY25 order booking | Better than previous year | FY25 |
| Input cost benefit duration | Continues until old orders at higher material costs are executed | Next few quarters |
| CBG large customer follow-on contracts | Commitment expected from the conglomerate | Beginning of next calendar year |
Key Metrics
| Metric | Q1 FY25 |
|---|---|
| Consolidated income from operations | ₹699 cr, vs ₹736 cr in Q1 FY24 |
| EBITDA margin improvement | 291 bps YoY, on account of moderation in input cost and revenue composition |
| PBT before exceptional items | ₹78.88 cr, vs ₹77.7 cr in Q1 FY24 |
| PBT after exceptional items | ₹107 cr, exceptional item pertains to sale of land |
| Profit after tax | ₹84.18 cr, vs ₹58.67 cr in Q1 FY24 |
| Order intake | ₹888 cr, 58% from domestic market |
| Order backlog | ₹4,044 cr, 67% domestic orders as of June 30, 2024 |
| Cash in hand | ₹830 cr as of June 30, 2024 |
| Revenue mix | 72% Bioenergy, 20% Engineering, 8% PHS |
| Export revenue share | 23% of Q1 FY25 revenue, 24% increase YoY |
| Order intake mix | 52% Bioenergy, 38% Engineering, 10% PHS |
| Domestic order book from starchy feedstock | Over 75% |
| Export component of order book | 42% |
| Slow-moving order book | ₹200–250 cr, less than 5% of total order book |
| FY25 CAPEX guidance | ₹75–100 cr |